Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase

European Journal of Pharmacology

Volumn 683, Issue 1-3, 2012, Pages 226-230

  Bar Am, Orit ^a   Gross, Aviva ^b   Friedman, Rachel ^b   Finberg, John P M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Teva Pharmaceutical Co Ltd   (Israel)

Author keywords

Baroreceptor reflex; Clorgyline; Nitroprusside; Phenylephrine; Selegiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; SELEGILINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD PRESSURE RESTING LEVEL; CARDIAC BARORECEPTOR REFLEX; CARDIOVASCULAR PARAMETERS; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SELECTIVITY; ENZYME INHIBITION; HEART RATE; HEART RATE BLOOD PRESSURE GAIN; HEART RATE PLATEAU LEVEL; HEART RATE RESTING LEVEL; MALE; MEAN ARTERIAL PRESSURE; MONOAMINE METABOLISM; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT;

ANIMALS; BAROREFLEX; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CLORGYLINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HYPERTENSION; HYPOTENSION; INJECTIONS, INTRAVENOUS; ISOENZYMES; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PRESSORECEPTORS; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84860498131     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.03.026     Document Type: Article

References (41)

1. Z.A. Abassi, O. Binah, and M.B.H. Youdim Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline Br. J. Pharmacol. 143 2004 371 373
2. D.M. Armstrong, C.A. Ross, V.M. Picket, T.H. Job, and D.J. Reis Distribution of dopamine-, noradrenaline-, adrenaline containing cell bodies in the rat medulla oblongata: demonstrated by the immunocytochemical localization of catecholamine biosynthetic enzymes Comp. Neurol. 212 1982 173 187
3. V. Aslanian, L. Lambas-Senas, and B. Renaud In vivo voltammetry in the B3 group of serotonin neurons of the rat medulla oblongata after drug-induced modifications of arterial pressure Life Sci. 43 1988 1031 1038
4. K.F. Bhattacharya, S. Nouri, C.W. Olanow, M.D. Yahr, and H. Kaufmann Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension Parkinsonism Relat. Disord. 9 2003 221 224
5. K.M. Campione Effect of antihypertensive (pargyline hydrochloride- methyclothiazide) therapy in three types of hypertension: preliminary report after one year of observation J. Am. Geriatr. Soc. 14 1966 490 496
6. A.M. Cesura, and A. Pletscher The new generation of monoamine oxidase inhibitors Prog. Drug Res. 38 1992 171 297
7. J.Y. Chan, M.Y. Tsou, W.B. Len, T.Y. Lee, and S.H. Chan Participation of noradrenergic neurotransmission in the enhancement of baroreceptor reflex response by substance P at the nucleus tractus solitarii of the rat: a reverse microdialysis study J. Neurochem. 64 1995 2644 2652
8. A. Churchyard, C.J. Mathias, P. Boonkongchuen, and A.J. Lees Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease J. Neurol. Neurosurg. Psychiatry 63 1997 228 234
9. J.P.M. Finberg, and M.B.H. Youdim Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours Neuropharmacology 43 2002 1110 1118
10. J.P.M. Finberg, J. Wang, D.S. Goldstein, I.J. Kopin, and K.S. Bankiewicz Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of l-DOPA in hemiparkinsonian rats J. Neurochem. 65 1995 1213 1220
11. J.P.M. Finberg, A. Gross, O. Bar-Am, R. Friedman, L. Loboda, and M.B.H. Youdim Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and l-DOPA in the rat Br. J. Pharmacol. 149 2006 647 656
12. J.A. Fuentes, A. Ordaz, and N.H. Neff Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats Eur. J. Pharmacol. 57 1979 21 27
13. J.R. Gill, D.T. Masson, and F.C. Bartter Effects of hydroxyamphetamine on the function of the sympathetic nervous system in normotensive subjects J. Pharmacol. Exp. Ther. 155 1967 288 295
14. D.S. Goldstein, L.T. Sewell, and Y. Sharabi Autonomic dysfunction in PD: a window to early detection? J. Neurol. Sci. 310 2011 118 122
15. A.R. Green, and M.B.H. Youdim Effects of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration Br. J. Pharmacol. 55 1975 415 422
16. D. Haberle, E. Szoko, and K. Magyar The influence of metabolism on the MAO-B inhibitory potency of selegiline Curr. Med. Chem. 9 2002 47 51
17. G.A. Head, and R. McCarty Vagal and sympathetic components of the heart rate range and gain of the baroreceptor-heart rate reflex in conscious rats J. Auton. Nerv. Syst. 21 1987 203 213
18. D.P. Holschneider, O.U. Scremin, K.P. Roos, D.R. Chialvo, K. Chen, and J.C. Shih Increased baroreceptor response in mice deficient in monoamine oxidase A and B Am. J. Physiol. Heart Circ. Physiol. 282 2002 H964 H972
19. S.T. Kaehler, C. Sinner, and A. Philippu Release of catecholamines in the locus coeruleus of free moving and anaesthetized normotensive and spontaneously hypertensive rats: effects of cardiovascular changes and tail pinch Naunyn Schmiedebergs Arch. Pharmacol. 361 2000 433 439
20. K. Kitahama, N. Sakamoto, A. Jouvet, I. Nagatsu, and J. Pearson Dopamine-beta-hydroxylase and tyrosine hydroxylase immunoreactive neurons in the human brainstem J. Chem. Neuroanat. 10 1996 137 146
21. C. Kobilansky, I. Lanzinger, and A. Philippu Release of endogenous catecholamines in the nucleus tractus solitarii during experimentally induced blood pressure changes Naunyn Schmiedebergs Arch. Pharmacol. 337 1988 125 130
22. I.J. Kopin, J.E. Fischer, J.M. Musacchio, W.D. Horst, and V.K. Weise False neurochemical transmitters and the mechanism of sympathetic blockade by monoamine oxidase inhibitors J. Pharmacol. Exp. Ther. 147 1965 186 193
23. K. Laine, M. Anttila, R. Huupponen, O. Matki-Ikola, and E. Heinonen Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding Clin. Neuropharmacol. 23 2000 22 27
24. I. Lamensdorf, M.B.H. Youdim, and J.P.M. Finberg The effect of long term treatment with monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo J. Neurochem. 67 1996 1532 1539
25. G. Lavian, J.P.M. Finberg, and M.B.H. Youdim The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine Clin. Neuropharmacol. 16 1993 S1 S7
26. W.R. Martin, J.W. Sloan, J.D. Sapira, and D.R. Jasinski Physiologic, subjective and behavioural effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man Clin. Pharmacol. Ther. 12 1971 245 260
27. J.F. Marwood, V. Huston, and K.T. Wall Some cardiovascular effects of monoamine oxidase inhibitors in unanaesthetized rats Clin. Exp. Pharmacol. Physiol. 12 1985 161 168
28. E. Moll, N. Neumann, W. Schmid-Burgk, M. Stabl, and R. Amrein Safety and efficacy during long-term treatment with moclobemide Clin. Neuropharmacol. 17 Suppl. 1 1994 S74 S87
29. S. Murase, K. Inui, and S. Nosaka Baroreceptor inhibition of the locus coeruleus noradrenergic neurons Neuroscience 61 1994 635 643
30. G.F. Oxenkrug Antidepressive and antihypertensive effects of MAO-A inhibition: role of N-acetylserotonin. A review Neurobiology (Bp.) 7 1999 213 224
31. V. Pursiainen, T.J. Korpelainen, H.T. Haapaniemi, A.K. Sotaniemi, and V.V. Myllyla Selegiline and blood pressure in patients with Parkinson's disease Acta Neurol. Scand. 115 2007 104 108
32. P. Rosenzweig, A. Patat, O. Curet, G. Durrieu, C. Dubruc, I. Zieleniuk, and E. Legagneux Clinical pharmacology of befloxatone: a brief review J. Affect. Disord. 51 1998 305 312
33. M.-K. Sun Central neural organization and control of sympathetic nervous system in mammals Prog. Neurobiol. 47 1995 157 233
34. M.K. Sun, and D.J. Reis Inhibition of protein kinase C differentially affects baroreflex inhibition and hypoxic excitation of medullary vasomotor neurons in rats Brain Res. 636 1994 245 252
35. J. Turkka, K. Suominen, U. Tolonen, K. Sotaniemi, and V.V. Myllylä Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease Neurology 48 1997 662 667
36. P.C. Waldmeier, A.E. Felner, and L. Maitre Long term effects of selective MAO inhibitors on MAO activity and amine metabolism M.B.H. Youdim, E.S. Paykel, Monoamine Oxidase Inhibitors: The State of the Art 1981 Wiley Chichester 87 102
37. J. Willoughby, V. Glover, and M. Sandler Histochemical localisation of monoamine oxidase A and B in rat brain J. Neural Transm. 74 1988 29 42
38. M.B.H. Youdim, and J.P.M. Finberg Monoamine oxidase inhibitor antidepressants D.G. Grahame-Smith, Psychopharmacology 1; Psychopharmacology Review Series 1982 Excerpta Medica Amsterdam 38 70
39. M.B.H. Youdim, and J.P.M. Finberg MAO type-B inhibitors as adjunct to l-DOPA therapy M.D. Yahr, K.J. Bergmann, Parkinson's Disease Adv. Neurol. vol. 45 1985 Raven Press New York, N.Y 127 136
40. M.B.H. Youdim, J.P.M. Finberg, and K.F. Tipton Amine oxidases U. Trendlenburg, N. Weiner, Handbook of Experimental Pharmacology 1988 Springer Verlag Berlin 119 192
41. M.B.H. Youdim, A. Gross, and J.P.M. Finberg Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B Br. J. Pharmacol. 132 2001 500 506